CN103328649B - 用于改善重组酶及其它蛋白的蛋白表达和分泌的新的信号序列 - Google Patents

用于改善重组酶及其它蛋白的蛋白表达和分泌的新的信号序列 Download PDF

Info

Publication number
CN103328649B
CN103328649B CN201180065369.5A CN201180065369A CN103328649B CN 103328649 B CN103328649 B CN 103328649B CN 201180065369 A CN201180065369 A CN 201180065369A CN 103328649 B CN103328649 B CN 103328649B
Authority
CN
China
Prior art keywords
signal sequence
protein
bip
polypeptide
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180065369.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103328649A (zh
Inventor
H·杜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CN103328649A publication Critical patent/CN103328649A/zh
Application granted granted Critical
Publication of CN103328649B publication Critical patent/CN103328649B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002Antibodies with enzymatic activity, e.g. abzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2434Glucanases acting on beta-1,4-glucosidic bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180065369.5A 2010-11-22 2011-11-22 用于改善重组酶及其它蛋白的蛋白表达和分泌的新的信号序列 Active CN103328649B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22
US61/415,926 2010-11-22
PCT/US2011/061862 WO2012071422A2 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins

Publications (2)

Publication Number Publication Date
CN103328649A CN103328649A (zh) 2013-09-25
CN103328649B true CN103328649B (zh) 2016-06-22

Family

ID=46146394

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180065369.5A Active CN103328649B (zh) 2010-11-22 2011-11-22 用于改善重组酶及其它蛋白的蛋白表达和分泌的新的信号序列

Country Status (19)

Country Link
US (1) US9279007B2 (enExample)
EP (2) EP3461905B1 (enExample)
JP (1) JP2014503198A (enExample)
KR (2) KR20190060888A (enExample)
CN (1) CN103328649B (enExample)
BR (1) BR112013012671B1 (enExample)
CA (1) CA2818689C (enExample)
CY (1) CY1121049T1 (enExample)
DK (2) DK3461905T3 (enExample)
ES (2) ES2687415T3 (enExample)
HR (1) HRP20181315T1 (enExample)
HU (1) HUE039070T2 (enExample)
LT (1) LT2643468T (enExample)
PL (1) PL2643468T3 (enExample)
PT (1) PT2643468T (enExample)
RS (1) RS57601B1 (enExample)
SI (1) SI2643468T1 (enExample)
SM (1) SMT201800466T1 (enExample)
WO (1) WO2012071422A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3164492T1 (sl) * 2014-07-03 2020-02-28 F. Hoffmann-La Roche Ag Sistem polipeptidne ekspresije
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
JP7341900B2 (ja) 2017-03-03 2023-09-11 オブシディアン セラピューティクス, インコーポレイテッド 免疫療法のためのcd19組成物及び方法
EP3635009B1 (en) 2017-06-07 2026-02-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
WO2019108924A2 (en) 2017-11-30 2019-06-06 Amicus Therapeutics, Inc. Cdkl5 expression variants and cdkl5 fusion proteins
IL276464B2 (en) 2018-02-07 2026-01-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
BR112020021962A2 (pt) * 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
MA52626A (fr) 2018-05-17 2021-03-24 Regeneron Pharma Anticorps anti-cd63, conjugués et leurs utilisations
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020077114A2 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN113454227B (zh) * 2018-12-19 2025-05-23 维萨梅布有限公司 编码蛋白质的rna
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
KR20220004696A (ko) * 2019-04-30 2022-01-11 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 폼페병의 치료에 유용한 조성물
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
KR20220044266A (ko) 2019-06-12 2022-04-07 옵시디안 테라퓨틱스, 인크. 조정 가능한 조절을 위한 ca2 조성물 및 방법
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
KR20230128001A (ko) 2020-12-01 2023-09-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 엔젤만 증후군의 치료를 위한 조성물 및 이의 용도
WO2023086939A1 (en) 2021-11-12 2023-05-19 Amicus Therapeutics, Inc. Compositions and methods for treating mucopolysaccharidosis iiia
WO2025264978A2 (en) 2024-06-20 2025-12-26 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a proteins and gene therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352286C (en) * 1998-11-24 2011-07-12 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kd heat shock protein
JP4834554B2 (ja) * 2003-11-06 2011-12-14 ジェネンコー・インターナショナル・インク 糸状菌におけるプロテアーゼ抑制剤及びその変異体の発現
DK2007885T3 (da) * 2006-04-11 2010-11-08 Csl Behring Gmbh Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (Bip) and inhibits its ATPase activity in human fibroblasts;Deng 等;《FASEB J》;20011130;第15卷(第13期);第2463-2470页 *
Targeting to the endoplasmic reticulum improves the folding of recombinant human telomerase reverse transcriptase;Wu等;《Protein Expr.purif》;20071130;第56卷(第1期);第8-19页 *
分子伴侣与MHC分子;吴涓涓;《国外医学(免疫学分册)》;20041105;第27卷(第6期);第358-361页 *

Also Published As

Publication number Publication date
EP3461905A1 (en) 2019-04-03
PT2643468T (pt) 2018-10-11
JP2014503198A (ja) 2014-02-13
US20140045216A1 (en) 2014-02-13
SMT201800466T1 (it) 2018-11-09
KR20190060888A (ko) 2019-06-03
RS57601B1 (sr) 2018-11-30
BR112013012671A2 (pt) 2016-10-11
EP2643468A4 (en) 2014-12-24
LT2643468T (lt) 2018-09-10
WO2012071422A2 (en) 2012-05-31
DK3461905T3 (da) 2020-11-02
KR20130121878A (ko) 2013-11-06
SI2643468T1 (sl) 2018-10-30
ES2687415T3 (es) 2018-10-25
EP2643468B1 (en) 2018-07-04
HUE039070T2 (hu) 2018-12-28
PL2643468T3 (pl) 2018-11-30
CA2818689A1 (en) 2012-05-31
DK2643468T3 (en) 2018-09-24
EP2643468A2 (en) 2013-10-02
HRP20181315T1 (hr) 2018-10-19
US9279007B2 (en) 2016-03-08
KR101984318B1 (ko) 2019-05-31
CN103328649A (zh) 2013-09-25
EP3461905B1 (en) 2020-08-05
CA2818689C (en) 2021-09-21
WO2012071422A3 (en) 2012-08-02
BR112013012671B1 (pt) 2022-03-03
ES2829199T3 (es) 2021-05-31
CY1121049T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
CN103328649B (zh) 用于改善重组酶及其它蛋白的蛋白表达和分泌的新的信号序列
BR112014004830B1 (pt) Célula de levedura geneticamente modificada, seu uso e método para produzir uma proteína ou polipeptídio recombinante de interesse
Dou et al. Type II transmembrane domain hydrophobicity dictates the cotranslational dependence for inversion
Merkaš et al. The MFα signal sequence in yeast-based protein secretion: challenges and innovations’
CN102659928B (zh) 一种人工合成的信号肽及其应用
CN110760541B (zh) 用中国仓鼠卵巢细胞表达外源蛋白时信号肽的选择方法及应用
EP0225860A2 (en) A method to export gene products to the growth medium of Gram negative bacteria
JP7242829B2 (ja) 新規細菌lpp突然変異体及び組換えタンパク質の分泌産生のためのその使用
CN103483423B (zh) 一种人工合成的信号肽及其应用
JP7800891B2 (ja) タンパク質生成に対するキメラシグナルペプチド
HK40006980A (en) Novel signal sequences to improve protein expression and secretion of recombinant enzymes and other proteins
HK1189913B (en) Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
HK1189913A (en) Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
Zhang et al. Intein-ubiquitin chimeric domain for coordinated protein coexpression
US20130059335A1 (en) Use of a genetically modified cell line expressing functional asialoglycoprotein receptor in the production of sialylated glycoproteins
CN114829578B (zh) 用于在发酵方法中释放重组蛋白的细菌菌株
CN102659927B (zh) 一种人工合成的信号肽及其应用
HK40102560A (zh) 用於增加蛋白质分泌的信号肽
CN104059128A (zh) 一种人工合成的信号肽及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: new jersey

Applicant after: Amicus Therapeutics Inc.

Address before: American Pennsylvania

Applicant before: Callidus Biopharma Inc

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CALLIDUS BIOPHARMA INC. TO: AMICUS THERAPEUTICS INC.

C14 Grant of patent or utility model
GR01 Patent grant